Skip to main content
Fig. 5 | BMC Bioinformatics

Fig. 5

From: A T-cell-related signature for prognostic stratification and immunotherapy response in hepatocellular carcinoma based on transcriptomics and single-cell sequencing

Fig. 5

T-cell-related prognostic signature (TRPS)-based treatment strategy for HCC. A The immunophenoscore in the high- and low-risk groups. B The TIDE score in the high- and low-risk groups. The percentage of SD/PD and CR/PR response subtypes in patients with different risk scores in the IMigor210 cohort (C), PRJEB25780 cohort (D) and GSE91061 cohort (E). F The IC50 values of axitinib, cisplatin, dabrafenib, gemcitabine, KRAS inhibitor, oxaliplatin, selumetinib, and sorafenib in the high- and low-risk groups. *P < 0.05, **P < 0.01, ***P < 0.001

Back to article page